Doctors have been installing electronic health record systems at a brisk clip in the last few years, but those systems might not be able to do everything that’s needed for the owners to qualify for meaningful use incentive payments, according to the Centers for Disease Control and Prevention (http://www.cdc.gov/nchs/data/databriefs/db111.pdf).

“From 2011 to 2012, the percentage of physicians who reported having a system that met the criteria for a basic system increased from 34 percent to 40 percent,” says the CDC’s National Center for Health Statistics. On the other hand “In 2012, 27 percent of office-based physicians who planned to apply or already had applied for meaningful use incentives had computerized systems with capabilities to support 13 of the Stage 1 core set objectives for meaningful use.”

There are 15 core set objectives that must be met in order for the government to underwrite up to $44,000 in new technology costs per physician. Unfortunately, “Some physicians with systems supporting the 13 core objectives examined in this report may not have a system that supports the remaining two objectives, as well as 5 of the 10 Menu Set objectives required for payment.”

Of those objectives, the CDC says that estimates of physician readiness to meet Stage 1 objectives were obtained by calculating EHRs that had all of the following features:

  • Recording patient demographic information, current problems, vital signs, smoking status, medications, and patient allergies
  • Having computerized provider order entry for medications
  • Sending prescriptions electronically to the pharmacy
  • Providing drug-drug and drug-allergy alerts
  • Having at least one clinical decision support rule implemented
  • Reporting clinical quality measures to federal or state agencies
  • Providing patients with an electronic copy of their health information and with clinical summaries for each visit

Percentage of office-based physicians with EHR systems

Source: National Ambulatory Medical Care Survey, 2001–2012

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.